The Food and Drug Administration (FDA) has passed the use of granisetron hydrochloride (GHCI) injections to prevent nausea caused by chemotherapy, pharmaceutical company Strides Arcolab has announced.
Officials said the treatment, a generic version of Roche Laboratories’ Kytril, had been given abbreviated new drug application (ANDA) approval.
Strides is now free to market the product in the US, with a launch expected in the near future.
It is the fourth treatment developed through the company’s partnership with Sagent Pharmaceuticals.
Ravi Seth, Strides’ chief executive officer, said: “With 20 ANDA approvals in the sterile injectables space, Strides has a significant and growing presence in the US market. Each approval constitutes an important milestone for the Strides-Sagent partnership which continues to acquire scale.”
Copyright Press Association 2010